amsacrine

PreclinicalSmall molecule

EEuropean Organisation for Research and Treatment of Cancer - EORTC

amsacrine is one of 13 small molecule programs targeting Stem Cell Transplantation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stem Cell TransplantationRecruiting

Stem Cell TransplantationPreclinical

Recruiting

Competition

Competitive Landscape

14 competitors in Stem Cell Transplantation

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Phase 3

31 2

Neupogen

EEastern Cooperative Oncology Group

Phase 3

23 3

Fludara

Sanofi

Phase 2

8 4

Atgam

Novartis

Phase 2

6 5

Medrol

Pfizer

Phase 2

6 6

Mesnex

BBaxter Healthcare Corporation

Phase 2

6 7

Benadryl

PParkedale

Phase 2

1 8

Tylenol

KKenvue Brands

Phase 2

1 9

Cytoxan

UUS Oncology Research

Phase 2

1 10

Peripheral Blood Stem Cell

FFred Hutchinson Cancer Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

Myelodysplastic Syndromes

NCT05807932

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia3 trials

Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

Completed·IInstitut Paoli-Calmettes·Phase 1/2·NCT00840684·135 enrolled

Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia

Terminated·UUniversity Hospital, Toulouse·Phase 3·NCT03765541·73 enrolled

Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002719·500 enrolled

Bone Marrow Transplantation2 trials

Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia

Unknown status·MMedical Research Council·Phase 3·NCT00002658·2,000 enrolled

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia

Completed·MMedical Research Council·Phase 3·NCT00003436·2,000 enrolled

Children1 trial

Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL

Completed·UUniversitätsklinikum Hamburg-Eppendorf·Phase 2/3·NCT01228331·745 enrolled

Leukemia1 trial

A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT01324063·160 enrolled

Myelodysplastic Syndromes1 trial

Phase-I/II Trial to Assess the Safety and Efficacy of Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML (FLAMSAClax

Recruiting·HHeinrich-Heine University, Duesseldorf·Preclinical·NCT05807932·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for amsacrine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — amsacrine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for amsacrine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — European Organisation for Research and Treatment of Cancer - EORTC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EEuropean Organisation for Research and Treatment of Cancer - EORTC

amsacrine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Acute Myeloid Leukemia3 trials

Bone Marrow Transplantation2 trials

Children1 trial

Leukemia1 trial

Myelodysplastic Syndromes1 trial

References

Drug Info

Quick Facts

Related News